SAN FRANCISCO — While the early hours of biotech’s biggest annual meeting didn’t bring any of the 10-figure transactions that tend to please investors, the J.P. Morgan Healthcare Conference offered plenty to debate when it comes to the future of medicine.
Here are some of the highlights so far, including a hot-button issue in Alzheimer’s disease, some family drama in oncology, and a reliably upbeat CEO forced to reckon with undeniably bad news.
A Bristol love story
Bristol-Myers Squibb (BMY) CEO Giovanni Caforio loves all his company’s drugs, but its BCMA-targeted bispecific antibody — an off-the-shelf multiple myeloma therapy ported over from Celgene — seemed to receive an inordinate amount of praise during his presentation and at the breakout session.
